Debra BorchardtOctober 18, 2023
The companies say the deal creates “strong synergies” by combining key assets, personnel, and capabilities.
Tag: Small Pharma
Debra BorchardtOctober 18, 2023
Adam JacksonSeptember 27, 2023
The DMT drug appeared more effective when combined with SSRIs.
Adam JacksonAugust 29, 2023
Cybin and Small Pharma holders will own around 74.5% and 25.5% of the combined company, respectively.
John SchroyerJune 29, 2023
Despite no revenue yet, the company expects to have enough cash to fund the 2024 fiscal year.
Dave HodesMay 24, 2022
As the industry matures, there are clear leaders in the pack of psychedelics companies who are positioned to continue driving industry development. Compass Pathways, Atai Life Sciences, and Cybin are generally considered the top three companies in the industry, asserting their dominance in the market, with Field Trip Health and Seelos Therapeutics as psychedelics companies […]
Dave HodesMay 11, 2022
One of the most important aspects of the psychedelics business—and one that is becoming more contentious—is about securing and protecting the patent for the specific molecule or synthetic that a psychedelics company is banking on because it can essentially protect the investment of millions of dollars a startup spends on setting up and running clinical […]
Dave HodesMay 4, 2022Small Pharma (OTC: DMTTF), a London-based neuropharmaceutical company focused on psychedelic-assisted therapies, made big news recently with the announcement of the first clinical trial in February 2021, using N, N-Dimethyltryptamine (DMT) to treat major depressive disorder. “We’re doing it in combination with psychotherapy, because we have reasons to believe that what psychedelics really do is […]
Get the latest cannabis news delivered right to your inbox
Unpack the industry with the daily cannabis newsletter for business leaders.